Characterizing Medical Care by Disease Phase in Metastatic Colorectal Cancer

被引:21
作者
Song, Xue [1 ]
Zhao, Zhongyun
Barber, Beth
Gregory, Christopher
Schutt, David
Gao, Sue
机构
[1] Thomson Reuters, 4301 Connecticut Ave, Washington, DC 20008 USA
关键词
D O I
10.1200/JOP.2011.000304
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To characterize patterns of medical care by disease phase in patients with newly diagnosed metastatic colorectal cancer (mCRC). Methods: Patients with mCRC newly diagnosed between 2004 and 2008 were selected from a large US national commercially insured claims database and were observed from initial mCRC diagnosis to death, disenrollment, or end of study period (July 31, 2009), whichever occurred first. The observation period was divided into three distinct phases of disease: diagnostic, treatment, and death. Within each phase, patterns of medical care were examined by the mutually exclusive service categories of inpatient, emergency room (ER), outpatient office and facility, outpatient pharmacy, chemotherapy, and biologic therapy, as measured by estimation of aggregate and category costs per patient per month. Results: A total of 6,675 patients with newly diagnosed mCRC were analyzed. Mean age was 64.1 years; 55.5% were males. Mean costs per patient per month for diagnostic, treatment, and death phases were $ 16,895, $ 8,891, and $ 27,554, respectively. Inpatient care was the primary driver of medical care for both the diagnostic (41.7% of costs) and death (71.4% of costs) phases. The largest category of medical care for the treatment phase was outpatient care (45.0% of costs). Chemotherapy and biologic therapy accounted for 15.6% and 17.6% of costs in the treatment phase, respectively. Conclusion: Substantial differences in patterns of medical care were found between mCRC disease phases. Inpatient care was the key driver of medical care in the diagnostic and death phases compared with outpatient care in the treatment phase.
引用
收藏
页码:25S / 30S
页数:6
相关论文
共 18 条
[1]   Using healthcare claims data for outcomes research and pharmacoeconomic analyses [J].
Birnbaum, HG ;
Cremieux, PY ;
Greenberg, PE ;
LeLorier, J ;
Ostrander, J ;
Venditti, L .
PHARMACOECONOMICS, 1999, 16 (01) :1-8
[2]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[3]   Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705
[4]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[5]  
Dukes C E, 1944, Proc R Soc Med, V37, P131
[6]   Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].
Giantonio, Bruce J. ;
Catalano, Paul J. ;
Meropol, Neal J. ;
O'Dwyer, Peter J. ;
Mitchell, Edith P. ;
Alberts, Steven R. ;
Schwartz, Michael A. ;
Benson, Al B., III .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544
[7]   A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
[8]   Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice [J].
Hess, Gregory P. ;
Wang, Peter Feng ;
Quach, David ;
Barber, Beth ;
Zhao, Zhongyun .
JOURNAL OF ONCOLOGY PRACTICE, 2010, 6 (06) :301-+
[9]   End-stage renal disease-associated managed care costs among patients with and without diabetes [J].
Joyce, AT ;
Iacoviello, JM ;
Nag, S ;
Sajjan, S ;
Jilinskaia, E ;
Throop, D ;
Pedan, A ;
Ollendorf, DA ;
Alexander, CM .
DIABETES CARE, 2004, 27 (12) :2829-2835
[10]   Metastatic colorectal cancer [J].
Kindler H.L. ;
Shulman K.L. .
Current Treatment Options in Oncology, 2001, 2 (6) :459-471